Omnix Medical founded in 2015, is developing novel antibiotic agents for the treatment of hospital-acquired infections involving drug resistant bacteria. Omnix’s technology is based on natural antimicrobial peptides, biochemically engineered to be compatible for therapeutic applications. Omnix’s lead molecule, OMN6, employs a unique mechanism of action, representing a new antibiotic class, characterized by a rapid-bactericidal effect. OMN6 was found to be active irrespective of resistance to other antibiotic drugs, and thus, offers a safer more efficient alternative to current therapies.
Dr. Moshik Cohen Kutner Co-Founder And CEO
Dr. Niv Bachnoff Co-Founder And CSO
Ms. Lihi Elyahu VP Operations & Human Resources
Ms. Bella Shusterman VP Clinical Development
Ms. Shira Mandel VP Research & Discovery
Ms. Noa Nur Director of Drug Discovery & Platform Development, IP Portfolio Manager
Dr. Jonathan Zazoun Head of CMC and Non-Dilutive Funding
Ms. Tamar Shachar VP Strategy and Drug Development
Ms. Ofra Barchad-Avitzur Director of Clinical Operations
Ms. Shelly Maximov Director of Preclinical Development & Regulation
Ms. Elital Chass-Maurice Director of Research & Drug Development
Ms. Orel Mayost Lev-Ari Research Associate
Ms. Katherine Kaufman Research Associate
Dr. Ori Heyman Research Associate